EGFR and non-small cell lung carcinoma: When assessing the molecular changes in EGFR, its amplification was associated with poorer RFS in early-stage EGFR-mutant LUAD [12], and a higher level of EGFR amplification correlated with poorer survival in surgically treated NSCLC patients [13].